A lab in central Ohio runs 300 injections a day across three GC systems. Their autosampler vials are a 2 mL, 9 mm screw-top with PTFE/silicone septa. In February, procurement changed the vial supplier to save $11 per case. In March, the second-shift lead called me about split peaks and ghost signals on the FID. The new septa were re-sealing at 38 punctures instead of the 90+ the old lot held. They had 14 cases on the shelf, all from the new vendor. One purchasing decision on MOQ had locked in a six-week supply of a consumable that degraded method precision by 4.7% RSD before anyone noticed. That is what happens when you plan reorder points around price instead of consumption rate, lead-time variance, and minimum order quantity. This article covers chromatography products MOQ lead time and reorder point planning as a single inventory problem, not three separate purchasing tasks.
Most labs set reorder points by feel. When the shelf looks low, someone emails purchasing. That works until a supplier moves a production line, a freight lane gets congested, or a key raw material allocation shifts. Then the shelf empties before the replacement order arrives. The fix is arithmetic, not software.
The reorder point for any chromatography consumable is:
Reorder point = (average daily consumption × lead time in days) + safety stock
Average daily consumption is not the number on the purchase order. It is the number of units actually consumed per working day, including weekends if the lab runs 24/7. A lab that runs 1,200 injections per week consumes roughly 1,200 vial/septum combinations per week, assuming no re-puncturing. If you re-puncture septa twice on average, consumption drops to 400 septa and 1,200 vials. Those are different reorder points for two SKUs that ship in the same box.
Lead time is not the vendor’s quoted transit time. It is the number of calendar days from the moment you release a purchase order to the moment the goods are physically on your receiving dock, inspected, and available to the bench. I have seen quoted lead times of 5 business days turn into 14 calendar days when you add order processing, export documentation, customs clearance, and internal receiving quarantine. For chromatography products sourced from overseas manufacturers, add 3 to 5 days for consolidation if the supplier ships LCL or airfreight on a fixed schedule.
Safety stock is the buffer against lead-time variance and consumption spikes. A common starting point is 25% of the lead-time demand. If your lead-time demand is 2,000 units, hold 500 units as safety stock. For critical consumables with a single qualified source, push that to 50%. For non-critical items with a second source already qualified, 15% is enough.
MOQ is a carrying-cost problem, not a price problem
Every supplier publishes a minimum order quantity. For chromatography consumables, MOQs cluster around three tiers. Septa and vial caps often carry MOQs of 1,000 to 5,000 pieces. Vials run 576 to 1,152 pieces per case, with MOQs of one case for common formats. Specialty items like 0.2 µm syringe filters for UHPLC sample prep can carry MOQs of 500 to 1,000 pieces. Columns are sold as single units, but distributors may impose a $500 or $1,000 order minimum that forces you to bundle unrelated SKUs.
The mistake is treating MOQ as a price threshold. It is a carrying-cost decision. When you order 5,000 septa because the MOQ says so, you are prepaying for inventory that sits on your shelf. The carrying cost of lab inventory includes capital tied up, storage space, risk of lot-to-lot drift, expiry dates on coated septa and derivatized vials, and the cost of re-qualifying a new lot if your current lot runs out before the next order arrives.
Here is a concrete calculation. A 2 mL, 9 mm screw-top vial with PTFE/silicone septum costs $0.19 per unit at 1,152 pieces per case. An MOQ of 5,000 pieces costs $950. If your lab consumes 1,000 pieces per month, that MOQ is a 5-month supply. At a carrying cost of 18% per year, you pay about $14.25 per month to hold that inventory. That sounds trivial until you multiply it across 40 consumable SKUs and add the cost of the shelf space, the expired septa you discard, and the re-validation runs when a new lot behaves differently.
The alternative is to negotiate MOQ waivers or split-case pricing. Many distributors will sell below MOQ for a 15 to 30% price premium. If the premium is less than your carrying cost plus your risk of lot failure, the waiver is the better deal. I have seen labs pay a 20% premium to buy 1,000 septa instead of 5,000, because their annual consumption was 2,400 and the 5,000-piece MOQ meant a 25-month supply. The premium cost them $38. The carrying cost and obsolescence risk on the larger order exceeded $120.
Lead-time variance matters more than average lead time
Average lead time is a comforting number. Variance is the number that causes stockouts. A supplier that quotes 7 days and delivers in 5 to 9 days is easy to plan for. A supplier that quotes 7 days and delivers in 3 to 21 days will cause a stockout eventually, even if the average is still 7 days.
For chromatography consumables, lead-time variance comes from three sources. First, manufacturing lot scheduling. A supplier that runs septa in batches every 6 weeks cannot ship your order in 7 days if you order the week after a batch closes. Second, customs and import clearance. One delayed container at a port can add 5 to 10 days to every order in that shipment. Third, quality hold. If an incoming lot fails the supplier’s dimensional or residual testing, they may need to re-run production before shipping your order.
You measure lead-time variance by tracking actual delivery dates against the PO date for at least 8 to 10 orders per supplier. Calculate the standard deviation of lead time in days. If the standard deviation is 3 days or less, a 25% safety stock buffer is reasonable. If it is 5 days or more, you need 40 to 50% safety stock or a second qualified source.
For a lab consuming 200 vials per day with a 10-day average lead time and a 4-day standard deviation, the reorder point calculation looks like this:
- Average daily consumption: 200 vials
- Average lead time: 10 days
- Lead-time demand: 2,000 vials
- Safety stock at 40% of lead-time demand: 800 vials
- Reorder point: 2,800 vials
If the same lab used only the average lead time with no safety stock, they would reorder at 2,000 vials. A single 4-day delay would empty the shelf. That is not a theoretical risk. It is the difference between a 2,000-vial reorder point and a 2,800-vial reorder point, and it costs about $152 in extra carrying cost per cycle to avoid a stockout that stops three instruments for a day.
Weeks of cover is the number your lab manager actually needs
Reorder points are useful for purchasing. Weeks of cover is the number your lab manager uses to decide whether to approve a purchase order or wait. Weeks of cover is current on-hand inventory divided by average weekly consumption.
For chromatography consumables, target weeks of cover depends on the item’s criticality and lead-time variance. For daily-use vials and septa with a single qualified source, target 6 to 8 weeks of cover. For solvents and mobile-phase additives with short expiry windows, target 2 to 3 weeks. For columns, which are expensive and method-specific, target 1 to 2 weeks of cover but keep a spare for every method that runs more than 20 hours per week.
The table below shows target weeks of cover for common chromatography consumables, based on lead-time variance and consumption volatility. These are the numbers I use when setting up a lab’s inventory plan.
| Consumable type | Typical consumption pattern | Lead-time variance | Target weeks of cover | Reorder point formula basis |
|---|---|---|---|---|
| Autosampler vials (2 mL, 9 mm) | High, steady daily use | Low to moderate (3-5 days) | 6-8 weeks | Daily use × lead time + 30% |
| Septa (PTFE/silicone, 9 mm) | High, steady daily use | Moderate (4-7 days) | 6-8 weeks | Daily use × lead time + 35% |
| Syringe filters (0.2 µm, 13 mm) | Moderate, batch-dependent | Low (2-4 days) | 3-4 weeks | Weekly use × lead time + 20% |
| GC inlet liners | Moderate, method-dependent | Moderate (5-8 days) | 4-6 weeks | Weekly use × lead time + 30% |
| HPLC columns | Low, method-specific | High (10-20 days for custom phases) | 1-2 weeks plus one spare per active method | One spare per method, reorder when spare is deployed |
| Mobile-phase solvents | High, but expiry-limited | Low (2-3 days) | 2-3 weeks | Weekly use × lead time + 15% |
| Ferrule and nut kits | Low, replacement-driven | Low (3-5 days) | 4-8 weeks | Monthly use × lead time + 25% |
Weeks of cover is not a static target. When a supplier announces a price increase, you may temporarily buy 10 to 12 weeks of cover to lock the old price. When a method is being phased out, you cut weeks of cover to zero for that method’s consumables and stop reordering. The number changes with the lab’s operational reality.
Two field cases where MOQ and lead time collided
Case one: a contract testing lab in New Jersey ran EPA Method 8270 for semi-volatiles on two GC-MS systems. Their vial consumption was 1,800 pieces per week. Their supplier quoted a 7-day lead time with an MOQ of 5,000 vials. The lab ordered 5,000 vials every 2.8 weeks. In September, the supplier’s production line went down for unscheduled maintenance. The quoted lead time stretched to 19 days. The lab had 2,100 vials on hand, which was 8.2 days of cover. They ran out on day 9. The fix was not a larger order. It was a second qualified source for the same 2 mL, 9 mm vial with the same dimensional tolerances and the same PTFE/silicone septum. They now split orders 70/30 between two suppliers and hold 8 weeks of cover, not 2.8.
Case two: a pharmaceutical QC lab in Illinois used 0.2 µm nylon syringe filters for sample prep before HPLC assay. The MOQ was 1,000 pieces. Their monthly consumption was 180 pieces. The MOQ represented a 5.5-month supply. The filters had a 24-month shelf life, so expiry was not the issue. The issue was lot-to-lot extractables. When a new lot arrived, the lab had to run a blank with every new lot to confirm no interfering peaks. With a 1,000-piece MOQ, they were re-qualifying lots every 5.5 months, which cost about 4 hours of analyst time and 2 hours of instrument time per qualification. The fix was to negotiate a 500-piece MOQ at a 12% price premium. The premium cost $0.02 per filter. The reduced qualification frequency saved more than that in labor and instrument time.
Set the reorder point from the method, not the catalog
The method defines consumption. A GC method with a 1 µL injection and a 2 mL vial consumes one vial and one septum per injection, assuming no re-puncture. An HPLC method with a 10 µL injection and a 2 mL vial consumes one vial per injection, but the septum is a cap liner that may be reused across multiple injections if the cap is not removed. A headspace method with a 20 mm crimp-top vial consumes one vial and one crimp cap per sample. Each method has its own consumption rate, and the reorder point for each consumable must be derived from the method’s daily sample count.
For a lab running 60 samples per day on one GC method, the daily consumption is 60 vials and 60 septa. If the lead time is 10 days and the safety stock is 30%, the reorder point for vials is 60 × 10 × 1.3 = 780 vials. For septa, the same calculation applies. But if the lab re-punctures septa twice on average, the septum consumption drops to 20 per day, and the reorder point for septa is 20 × 10 × 1.3 = 260 septa. The vial and septum reorder points are different numbers, and they should be tracked as separate SKUs even if they ship in the same case.
This is where vials with caps become a procurement decision, not just a product category. Some labs buy pre-assembled vials with caps to reduce handling time. Others buy vials and caps separately to control septum quality independently. The reorder point for a pre-assembled vial/cap unit is one number. The reorder point for separate vials and caps is two numbers. The inventory plan must match the physical reality of what is on the shelf.
What a reorder point does not solve
A reorder point tells you when to order. It does not tell you what to order. Dimensional fit is still the first filter. A 2 mL, 9 mm screw-top vial from one supplier may not seal correctly with a cap from another supplier, even if both claim 9 mm compatibility. The thread pitch, the glass shoulder geometry, and the septum compression characteristics all affect the seal. Agilent GC columns and accessories are designed to work with specific inlet dimensions and ferrule geometries. A reorder point for a column does not help if the replacement column has a different phase selectivity or a different inner diameter.
Similarly, a reorder point does not solve the problem of lot-to-lot variability. Septa from the same supplier can vary in puncture resistance, resealability, and extractables profile between production lots. Restek’s technical resources document the importance of lot traceability for critical consumables. When you receive a new lot, run a blank injection and a standard injection before putting the lot into routine use. The reorder point should include enough buffer to allow for this qualification step without stopping the lab.
Supplier qualification is part of the reorder point calculation
A reorder point assumes the supplier will deliver on time and in spec. That assumption fails often enough that the reorder point must include a qualification buffer. For a new supplier, the qualification process includes dimensional checks with calipers or a vision system, a puncture test on a representative number of septa, a solvent compatibility test, and a chromatographic blank run. This takes 2 to 5 working days. If you are switching suppliers, order the new supplier’s product while you still have 4 to 6 weeks of cover from the old supplier. Run the qualification in parallel. Do not wait until the old stock is gone.
For vial suppliers and septum manufacturers, the qualification criteria should include dimensional tolerance on the vial ID and OD, septum thickness, PTFE layer thickness, and silicone durometer. A septum with a PTFE layer of 0.010 inch behaves differently from one with a 0.020 inch layer. The thinner PTFE layer may re-seal better after multiple punctures, but it may also leach more silicone into the sample. The thicker PTFE layer is more inert but may not re-seal as well. These are the trade-offs that a reorder point calculation does not capture, but a supplier qualification protocol does.
Thermo Fisher’s chromatography and sample handling line includes vials, caps, and septa with documented lot-to-lot consistency. When you qualify a supplier, ask for the certificate of analysis for the specific lot you are receiving. Compare the measured values against the supplier’s published specifications. If the supplier cannot provide a lot-specific certificate, treat that as a lead-time variance risk and increase your safety stock.
Regulatory methods add a reorder point constraint
Labs running EPA SW-846 methods face a specific constraint: the consumables must meet the method’s requirements for cleanliness, inertness, and dimensional compatibility. A reorder point that triggers an order for a non-compliant consumable is worse than no reorder point at all. For EPA methods, the vial and septum must not contribute extractables that interfere with the target analytes. This is a performance specification, not a dimensional one. A supplier can meet the dimensional spec and still fail the extractables test.
When a lab switches vial suppliers for an EPA method, the new lot must be verified with a method blank and a mid-level calibration standard. This verification run consumes vials, septa, solvent, and instrument time. The reorder point must account for this consumption. If the verification run uses 20 vials and 20 septa, those are not available for routine samples. Add the verification consumption to the safety stock calculation.
For labs running USP methods, the same logic applies. USP chapter <621> defines system suitability requirements, not consumable specifications. The consumables must be qualified within the context of the specific method. A reorder point that triggers a new lot without a qualification plan is a compliance risk. The qualification plan is not a purchasing task. It is a laboratory task that purchasing must accommodate in the inventory timeline.
Decision checklist for setting a reorder point
Use this checklist when setting or revising a reorder point for any chromatography consumable. Each item requires a number, not a judgment call.
- Average daily consumption: calculated from the last 90 days of actual usage, not purchase orders.
- Lead time in calendar days: measured from PO release to goods on the receiving dock, including customs and quarantine.
- Lead-time standard deviation: calculated from the last 8 to 10 orders. If fewer than 8 data points, use 40% of average lead time as a conservative safety stock.
- Safety stock percentage: 25% for low-variance items, 40% for high-variance items, 50% for single-source critical items.
- MOQ vs. consumption rate: if MOQ exceeds 3 months of consumption, negotiate a waiver or split-case pricing.
- Lot qualification consumption: the number of vials, septa, or filters consumed during new-lot verification runs.
- Weeks of cover target: 6-8 weeks for daily-use vials and septa, 3-4 weeks for filters, 1-2 weeks for columns plus one spare per active method.
- Second source status: if no second source is qualified, increase safety stock by 15 to 25 percentage points.
The reorder point is not a static number. It changes when the method changes, when the supplier changes, when the lead time changes, or when the consumption rate changes. Review it quarterly, or whenever a method is added, removed, or modified.
The decision rule is this: set the reorder point from measured consumption and measured lead-time variance, not from the supplier’s MOQ. Buy below MOQ when the carrying cost and lot-qualification cost exceed the price premium for a smaller order. Hold weeks of cover based on the item’s criticality and lead-time variance, not on a blanket policy. And qualify every new lot before it reaches the bench, because a reorder point that triggers a bad lot is a stockout in disguise.
References & further reading
Related resources from our lab consumables network:
- Chromatography Products at chromatographyselling.com
- Aijiren at aijirentech.com
- Vials With Caps at vialswithcaps.com
- Vial Supplier at vialsupplier.com
External references and standards: